Prevention, Diagnosis and Therapy of HNSCC (Head and Neck Squamous Cell Carcinoma)

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (30 April 2022) | Viewed by 3724

Special Issue Editors


E-Mail Website
Guest Editor
Universitätsklinikum Ulm, Ulm, Germany
Interests: molecular oncology; tumor immunology; HNSCC
Division of Molecular Medicine, Ruđer Bošković Institute, Zagreb, Croatia
Interests: HPV; miRNA; HNSCC; cervical cancer; DNA viruses; biomarkers; epidemiology

Special Issue Information

Dear Colleagues,

Head and neck squamous cell carcinoma (HNSCC) is the most common cancer type arising in the head and neck region and the sixth most often occurring tumor entity globally. Despite great efforts to improve the therapy for HNSCC and to develop new therapeutic options, the 5-year survival rate has remained persistently low over the past 10 years. Possibly, this observation is based on the fact that HNSCC is a very heterogeneous type of cancer which affects different locations of the head and neck area and is elicited by different causes: alcohol and tobacco consumption as well as infections with human papilloma virus (HPV) and Epstein–Barr virus (EBV) are the main etiological factors. Recent research indicates the need to consider tumor localization together with etiological factors to adequately interpret clinical as well as molecular biological data for the development of successful beneficial treatment approaches for HNSCC. Additionally, deeper molecular insights into the tumor microenvironment, tumor-induced immune responses, but also into genetic, epigenetic, and transcriptionally regulated mechanisms leading to the development of HNSCC are needed to understand this disease and to ultimately develop therapeutic opportunities based on defined biomarkers.

Therefore, for this Special Issue, we are inviting researchers and clinician scientists to submit their findings describing recent advances in the diagnosis, therapy, prevention, and further understanding of the complex biology of HNSCC.

Prof. Dr. Cornelia Brunner
Dr. Ivan Sabol
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • HNSCC
  • HPV
  • genetic and epigenetic alterations
  • transcriptional regulation, tumor microenvironment
  • tumor induced immune responses
  • liquid biopsy
  • immunosuppression
  • immune monitoring
  • immunotherapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2564 KiB  
Article
EPHA3 Contributes to Epigenetic Suppression of PTEN in Radioresistant Head and Neck Cancer
by Song-Hee Kim, Byung-Chul Kang, Daseul Seong, Won-Hyeok Lee, Jae-Hee An, Hyoung-Uk Je, Hee-Jeong Cha, Hyo-Won Chang, Sang-Yoon Kim, Seong-Who Kim and Myung-Woul Han
Biomolecules 2021, 11(4), 599; https://doi.org/10.3390/biom11040599 - 18 Apr 2021
Cited by 10 | Viewed by 2972
Abstract
EPHA3, a member of the EPH family, is overexpressed in various cancers. We demonstrated previously that EPHA3 is associated with radiation resistance in head and neck cancer via the PTEN/Akt/EMT pathway; the inhibition of EPHA3 significantly enhances the efficacy of radiotherapy in vitro [...] Read more.
EPHA3, a member of the EPH family, is overexpressed in various cancers. We demonstrated previously that EPHA3 is associated with radiation resistance in head and neck cancer via the PTEN/Akt/EMT pathway; the inhibition of EPHA3 significantly enhances the efficacy of radiotherapy in vitro and in vivo. In this study, we investigated the mechanisms of PTEN regulation through EPHA3-related signaling. Increased DNA methyltransferase 1 (DNMT1) and enhancer of zeste homolog 2 (EZH2) levels, along with increased histone H3 lysine 27 trimethylation (H3K27me3) levels, correlated with decreased levels of PTEN in radioresistant head and neck cancer cells. Furthermore, PTEN is regulated in two ways: DNMT1-mediated DNA methylation, and EZH2-mediated histone methylation through EPHA3/C-myc signaling. Our results suggest that EPHA3 could display a novel regulatory mechanism for the epigenetic regulation of PTEN in radioresistant head and neck cancer cells. Full article
Show Figures

Figure 1

Back to TopTop